Your browser is no longer supported. Please, upgrade your browser.
LXRX Lexicon Pharmaceuticals, Inc. daily Stock Chart
Lexicon Pharmaceuticals, Inc.
Index- P/E7.11 EPS (ttm)0.19 Insider Own0.60% Shs Outstand107.07M Perf Week-9.52%
Market Cap145.70M Forward P/E- EPS next Y-0.97 Insider Trans0.00% Shs Float105.84M Perf Month-8.28%
Income39.30M PEG- EPS next Q0.26 Inst Own- Short Float9.57% Perf Quarter-23.56%
Sales320.30M P/S0.45 EPS this Y197.90% Inst Trans-0.11% Short Ratio7.89 Perf Half Y-42.17%
Book/sh-0.10 P/B- EPS next Y19.80% ROA10.10% Target Price- Perf Year-63.56%
Cash/sh1.84 P/C0.72 EPS next 5Y- ROE48.20% 52W Range1.34 - 5.33 Perf YTD-67.95%
Dividend- P/FCF- EPS past 5Y23.30% ROI40.70% 52W High-75.05% Beta1.51
Dividend %- Quick Ratio2.50 Sales past 5Y69.70% Gross Margin99.20% 52W Low-0.75% ATR0.08
Employees184 Current Ratio2.50 Sales Q/Q-5.20% Oper. Margin15.70% RSI (14)32.92 Volatility4.68% 5.52%
OptionableYes Debt/Eq- EPS Q/Q-197.80% Profit Margin12.30% Rel Volume0.73 Prev Close1.36
ShortableYes LT Debt/Eq- EarningsJul 30 BMO Payout0.00% Avg Volume1.28M Price1.33
Recom2.80 SMA20-9.11% SMA50-16.56% SMA200-37.44% Volume934,259 Change-2.21%
Dec-11-19Downgrade Gabelli & Co Buy → Hold
Nov-08-19Downgrade Citigroup Buy → Neutral $3 → $4
Sep-11-19Upgrade Gabelli & Co Hold → Buy $3
Jul-29-19Downgrade Stifel Buy → Hold $10 → $4
Mar-25-19Upgrade Gabelli & Co Sell → Hold
Jul-31-18Reiterated Stifel Buy $24 → $23
Feb-23-18Downgrade Needham Buy → Hold
Feb-14-18Downgrade JP Morgan Neutral → Underweight $10
Mar-01-17Reiterated Wedbush Outperform $33 → $38
Mar-01-17Reiterated H.C. Wainwright Buy $26 → $27
Oct-07-16Initiated H.C. Wainwright Buy $26
Aug-05-16Reiterated Wedbush Outperform $30 → $31
Aug-02-16Initiated Citigroup Buy $21
Mar-02-16Reiterated Wedbush Outperform $26 → $28
Nov-09-15Reiterated Wedbush Outperform $19 → $26
Sep-28-15Upgrade Gabelli & Co Sell → Hold
Sep-18-15Downgrade Gabelli & Co Hold → Sell
Aug-10-15Downgrade JP Morgan Overweight → Neutral
Aug-19-14Downgrade Gabelli & Co Buy → Hold
Jun-26-12Reiterated Stifel Nicolaus Buy $3 → $4
Sep-23-20 06:43PM  
Sep-14-20 09:46AM  
Sep-08-20 04:05PM  
Sep-04-20 08:00AM  
Sep-03-20 06:00PM  
Aug-24-20 11:35AM  
Aug-10-20 11:52AM  
Aug-03-20 07:25AM  
Aug-02-20 09:54AM  
Jul-30-20 06:00PM  
Jul-23-20 07:00AM  
Jul-22-20 12:32PM  
Jul-21-20 07:00AM  
Jul-20-20 07:00AM  
Jul-14-20 01:19PM  
Jul-04-20 02:02PM  
Jun-13-20 11:01AM  
Jun-11-20 05:22PM  
May-27-20 07:00AM  
May-13-20 05:30PM  
Apr-27-20 06:33PM  
Apr-22-20 05:41PM  
Apr-20-20 10:04AM  
Apr-07-20 07:00AM  
Mar-30-20 11:11AM  
Mar-20-20 07:44AM  
Mar-19-20 04:01PM  
Mar-13-20 08:05AM  
Mar-12-20 01:40PM  
Mar-05-20 07:00AM  
Mar-04-20 12:30PM  
Jan-24-20 03:00PM  
Jan-20-20 04:01PM  
Jan-09-20 02:50PM  
Jan-06-20 06:09PM  
Dec-20-19 08:31AM  
Dec-19-19 08:28PM  
Dec-13-19 08:52AM  
Dec-05-19 12:54PM  
Dec-03-19 07:00AM  
Dec-02-19 11:09AM  
Nov-26-19 04:01PM  
Nov-15-19 11:17PM  
Nov-14-19 08:09PM  
Nov-13-19 08:39AM  
Nov-07-19 11:15AM  
Oct-31-19 04:01PM  
Oct-30-19 10:34AM  
Oct-29-19 07:05AM  
Oct-15-19 11:29AM  
Oct-13-19 05:15PM  
Oct-02-19 04:01PM  
Sep-30-19 10:05AM  
Sep-23-19 08:54AM  
Sep-18-19 08:42AM  
Sep-15-19 11:18AM  
Sep-11-19 07:42PM  
Sep-10-19 04:51PM  
Sep-09-19 03:38PM  
Sep-05-19 11:12AM  
Aug-30-19 07:00AM  
Aug-27-19 01:59AM  
Aug-20-19 07:15PM  
Aug-09-19 07:00AM  
Aug-08-19 05:23PM  
Jul-31-19 11:36AM  
Jul-30-19 12:59PM  
Jul-29-19 04:35PM  
Jul-27-19 05:05AM  
Jul-26-19 05:58PM  
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the treatment of type 1 and is in Phase III clinical trials for the treatment of type 2 diabetes; LX9211, which is in Phase I clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SOBECKI CHRISTOPHER JDirectorApr 26Option Exercise0.003,4660140,759Apr 27 04:48 PM
Swain Judith LDirectorApr 26Option Exercise0.003,466016,368Apr 27 04:49 PM
Palantoni FrankDirectorApr 26Option Exercise0.003,466016,368Apr 27 04:48 PM
NIES ALAN SDirectorApr 26Option Exercise0.003,466017,082Apr 27 04:47 PM
DEBBANE RAYMONDDirectorApr 26Option Exercise0.003,4660316,883Apr 27 04:45 PM
LEFKOWITZ ROBERT J MDDirectorApr 26Option Exercise0.003,466016,368Apr 27 04:46 PM
BARKER SAM LDirectorApr 26Option Exercise0.003,466055,653Apr 27 04:44 PM
Amouyal PhilippeDirectorApr 26Option Exercise0.003,466016,368Apr 27 04:43 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.